Tomoya Kubota

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Vera Bril, Artur Drużdż, Julian Großkreutz et al. · The Lancet Neurology · 2023 · 227 citations

Clinical Trials, Generalised Myasthenia Gravis, Pharmacotherapy +3

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

James F. Howard, Saskia Bresch, Angela Genge et al. · The Lancet Neurology · 2023 · 213 citations

Medicine, Surgery, Clinical Trials +1

Native Chemical Ligation at Asx-Cys, Glx-Cys: Chemical Synthesis and High-Resolution X-ray Structure of ShK Toxin by Racemic Protein Crystallography

Bobo Dang, Tomoya Kubota, Kalyaneswar Mandal et al. · Journal of the American Chemical Society · 2013 · 94 citations

CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation

Tomoya Kubota, C Nakajima-Taniguchi, Tsuyoshi Fukuda et al. · The Pharmacogenomics Journal · 2006 · 90 citations

Influence Withdrawal Symptoms, Tobacco Control, Substance Abuse +9